Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Corestemchemon's current 10-Year Share Buyback Ratio was -7.60%.
XKRX:166480's 10-Year Share Buyback Ratio is ranked better than 61.79% of 670
companies
in the Biotechnology industry
Industry Median: -12.05
vs XKRX:166480: -7.60
Corestemchemon (XKRX:166480) 10-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Corestemchemon 10-Year Share Buyback Ratio Related Terms
XKRX:166480 vs VRTX, REGN, ALNY: 10-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Corestemchemon's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corestemchemon 10-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corestemchemon's 10-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Corestemchemon's 10-Year Share Buyback Ratio falls into.
Corestemchemon 10-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 10-Year Share Buyback Ratio of -7.60 mean?
Corestemchemon (XKRX:166480) has a 10-Year Share Buyback Ratio of -7.60 as of Mar. 2026. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Corestemchemon and its competitors. According to the industry distribution chart, Corestemchemon ranks #256 out of 670 companies in the Biotechnology industry, placing it in the top 38.2%.
Is Corestemchemon's 10-Year Share Buyback Ratio too high?
Corestemchemon's current 10-Year Share Buyback Ratio is -7.60. Based on the distribution chart, Corestemchemon ranks #256 out of 670 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Corestemchemon has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corestemchemon's 10-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Corestemchemon ranks #256 out of 670 companies for 10-Year Share Buyback Ratio. This puts Corestemchemon in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Biotechnology company?
A good 10-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Corestemchemon and its competitors. Corestemchemon's current 10-Year Share Buyback Ratio is -7.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corestemchemon stock overvalued right now?
Based on GuruFocus' analysis, Corestemchemon (XKRX:166480) is currently considered Modestly Overvalued. The stock's GF Value™ is ₩1,742.07, compared to a current price of ₩2,155.00 — trading 23.7% above its estimated fair value. The current 10-Year Share Buyback Ratio is -7.60. Corestemchemon's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Corestemchemon (XKRX:166480), the current 10-Year Share Buyback Ratio is -7.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corestemchemon (XKRX:166480) Overvalued in 2026?
Based on GuruFocus' analysis, Corestemchemon stock appears to be overvalued.
The current stock price of ₩2,155.00 is trading 23.7% above its estimated GF Value™ of ₩1,742.07.
GuruFocus considers Corestemchemon to be Modestly Overvalued.
Key valuation signals for XKRX:166480:
10-Year Share Buyback Ratio: -7.60
GF Value™: ₩1,742.07 vs. price of ₩2,155.00 (23.7% above fair value)
No single metric tells the full story. See the XKRX:166480 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.
46GF Score
Get the complete analysis for XKRX:166480
10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:166480 has been successfully added to your 